Novel synthetic treatment options for migraine

References

• Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17.
   PubMed Web of Science ®Google Scholar
• Martelletti P, Schwedt TJ, Lanteri-Minet M, et al. My migraine voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018;19(1):115.
   PubMed Web of Science ®Google Scholar
• Negro A, Spuntarelli V, Sciattella P, et al. Rapid referral for headache management from emergency department to headache centre: four years data. J Headache Pain. 2020;21(1):25.
   PubMed Web of Science ®Google Scholar
• Serrano D, Lipton RB, Scher AI, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18(1):101.
   PubMedGoogle Scholar
• Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain. 2011;12(6):593–601.
   PubMed Web of Science ®Google Scholar
• Martelletti P, Katsarava Z, Lampl C, et al. Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation. J Headache Pain. 2014;15:47.
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and lifting the burden: the global campaign against headache. J Headache Pain. 2019;20(1):57.
   PubMed Web of Science ®Google Scholar
• Antonaci F, Ghiotto N, Wu S, et al. Recent advances in migraine therapy. Springerplus. 2016;5:637.
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22(8):633–658.
   PubMed Web of Science ®Google Scholar
• Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43(4):376–388.
   PubMed Web of Science ®Google Scholar
• Lionetto L, Borro M, Curto M, et al. Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. Expert Opin Drug Metab Toxicol. 2016;12(4):399–406.
   PubMed Web of Science ®Google Scholar
• Thorlund K, Toor K, Wu P, et al. Comparative tolerability of treatments for acute migraine: a network meta-analysis. Cephalalgia. 2017;37(10):965–978.
   PubMed Web of Science ®Google Scholar
• Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44(5):414–425.
   PubMed Web of Science ®Google Scholar
• Rubio-Beltrán E, Labastida-Ramírez A, Villalón CM, et al. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther. 2018;186:88–97.
   PubMed Web of Science ®Google Scholar
• PJ G, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622.
   PubMed Web of Science ®Google Scholar
• Liu Y, Broman J, Zhang M, et al. Brainstem and thalamic projections from a craniovascular sensory nervous centre in the rostral cervical spinal dorsal horn of rats. Cephalalgia. 2009;29(9):935–948.
   PubMed Web of Science ®Google Scholar
• Malick A, Burstein R. Cells of origin of the trigeminohypothalamic tract in the rat. J Comp Neurol. 1998;400(1):125–144.
   PubMed Web of Science ®Google Scholar
• Malick A, Strassman RM, Burstein R. Trigeminohypothalamic and reticulohypothalamic tract neurons in the upper cervical spinal cord and caudal medulla of the rat. J Neurophysiol. 2000;84(4):2078–2112.
   PubMed Web of Science ®Google Scholar
• Williams MN, Zahm DS, Jacquin MF. Differential foci and synaptic organization of the principal and spinal trigeminal projections to the thalamus in the rat. Eur J Neurosci. 1994;6(3):429–453.
   PubMed Web of Science ®Google Scholar
• Noseda R, Jakubowski M, Kainz V, et al. Cortical projections of functionally identified thalamic trigeminovascular neurons: implications for migraine headache and its associated symptoms. J Neurosci. 2011;31(40):14204–14217.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Uddman R. Neurobiology in primary headaches. Brain Res Brain Res Rev. 2005;48(3):438–456.
   PubMedGoogle Scholar
• Gallai V, Sarchielli P, Floridi A, et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 1995;15(5):384–390.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183–187.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33(1):48–56.
   PubMed Web of Science ®Google Scholar
• Juhasz G, Zsombok T, Jakab B, et al. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia. 2005;25(3):179–183.
   PubMed Web of Science ®Google Scholar
• Lassen LH, Jacobsen VB, Haderslev PA, et al. Involvement of calcitonin gene related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients. J Headache Pain. 2008;9(3):151–157.
   PubMed Web of Science ®Google Scholar
• Hansen JM, Hauge AW, Olesen J, et al. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30(10):1179–1186.
   PubMed Web of Science ®Google Scholar
• Asghar MS, Hansen AE, Amin FM, et al. Evidence for a vascular factor in migraine. Ann Neurol. 2011;69(4):635–645.
   PubMed Web of Science ®Google Scholar
• Recober A, Kuburas A, Zhang Z, et al. Role of calcitonin gene-related peptide in light aversive behavior: implications for migraine. J Neurosci. 2009;29(27):8798–8804.
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, Meijer J, Villalón CM, et al. Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci. 2016;37(9):779–788.
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollón E, Larrosa D, Ramón C, et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81(14):1191–1196.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC. Does sumatriptan cross the blood-brain barrier in animals and man? J Headache Pain. 2010;11(1):5–12.
   PubMed Web of Science ®Google Scholar
• Sakai Y, Dobson C, Diksic M, et al. Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis. Neurology. 2008;70(6):431–439.
   PubMed Web of Science ®Google Scholar
• Evans DC, O’Connor D, Lake BG, et al. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003;31(7):861–869.
   PubMed Web of Science ®Google Scholar
• Negro A, Koverech A, Martelletti P. Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. J Pain Res. 2018;11:515–526.
   PubMed Web of Science ®Google Scholar
• Lundblad C, Haanes KA, Grande G, et al. Experimental inflammation following dural application of complete Freund’s adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage. J Headache Pain. 2015;16:91.
   PubMed Web of Science ®Google Scholar
• Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Ann Rev Physiol. 2013;75:365–391.
   PubMed Web of Science ®Google Scholar
• Wainscott DB, Krushinski JH Jr, Audia JE, et al. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties. Naunyn Schmiedebergs Arch Pharmacol. 2005;371(3):169–177.
   PubMed Web of Science ®Google Scholar
• Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA, et al. Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan. Br J Pharmacol. 2019 Dec;176(24):4681–4695.
   PubMed Web of Science ®Google Scholar
• Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010;30(10):1159–1169.
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Färkkilä M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – a randomised proof-of-concept trial. Cephalalgia. 2010;30(10):1170–1178.
   PubMed Web of Science ®Google Scholar
• Färkkilä M, Diener HC, Géraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11(5):405–413.
   PubMed Web of Science ®Google Scholar
• Kuca B, Silberstein SD, Wietecha L, et al. COL MIG-301 Study Group. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018;91(24):e2222–e2232.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894–1904.
   PubMed Web of Science ®Google Scholar
• Brandes JL, Klise S, Krege JH, et al. Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia. 2019;39(11):1343–1357.
   PubMed Web of Science ®Google Scholar
• Ter Haar E, Koth CM, Abdul-Manan N, et al. Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. Structure. 2010;18(9):1083–1093.
   PubMed Web of Science ®Google Scholar
• Lynch JJ, Shen YT, Pittman TJ, et al. Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8–37) on myocardial reactive hyperemic response in conscious dogs. Eur J Pharmacol. 2009;623(1–3):96–102.
   PubMed Web of Science ®Google Scholar
• Verheggen R, Bumann K, Kaumann AJ. BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: comparison with CGRP(8–37). Br J Pharmacol. 2002;136(1):120–126.
   PubMed Web of Science ®Google Scholar
• Chan KY, Edvinsson L, Eftekhari S, et al. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther. 2010;334(3):746–752.
   PubMed Web of Science ®Google Scholar
• Petersen KA, Birk S, Lassen LH, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005;25(2):139–147.
   PubMed Web of Science ®Google Scholar
• Olesen J, Diener C, Husstedt IW, et al. BIBN 4096 BS clinical proof of concept study group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104–1110.
   PubMed Web of Science ®Google Scholar
• Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009;73(12):970–977.
   PubMed Web of Science ®Google Scholar
• Ho AP, Dahlof CG, Silberstein SD, et al. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia. 2010;30(12):1443–1457.
   PubMed Web of Science ®Google Scholar
• Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31(6):712–722.
   PubMed Web of Science ®Google Scholar
• Diener HC, Barbanti P, Dahlof C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011;31(5):573–584.
   PubMed Web of Science ®Google Scholar
• Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34(2):114–125.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Conway CM, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant 75 mg, an oral CGRP receptor antagonist, for the acute treatment of migraine: results from a double-blind, randomized, placebo-controlled trial, study. In 60th Annu Meet Am Headache Soc (AHS); June 28–July 1; San Francisco; 2018. p. PS123LB.
   Google Scholar
• Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142–149.
   PubMed Web of Science ®Google Scholar
• Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737–745.
   PubMed Web of Science ®Google Scholar
• An open-label, intermediate size, expanded access study of BHV-3000 in the acute treatment of migraine (NCT03934086). [cited 2020 May 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT03934086
   Google Scholar
• Efficacy and safety trial of rimegepant for migraine prevention in Adults (NCT03732638). [cited 2020 May 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT03732638
   Google Scholar
• Trial for treatment refractory trigeminal neuralgia (NCT03941834). [cited 2020 Jul 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03941834
   Google Scholar
• Open label safety study in acute treatment of migraine (NCT03266588). [Last accessed 2020 Jul 29]. Available from: https://clinicaltrials.gov/show/NCT03266588
   Google Scholar
• A pharmacokinetic study of MK-1602 in the treatment of acute migraine (MK-1602-007) (NCT01657370). [cited 2020 May 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT01657370
   Google Scholar
• Voss T, Lipton RB, Dodick DW, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36(9):887–898.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230–2241.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887–1898.
   PubMed Web of Science ®Google Scholar
• An extension study to evaluate the long-term safety and tolerability of ubrogepant in the treatment of migraine. [ cited 2020 May 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT02873221
   Google Scholar
• Efficacy, safety, and tolerability of multiple dosing regimens of oral atogepant (AGN-241689) in episodic migraine prevention. [cited 2020 May 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT02848326
   Google Scholar
• To evaluate the safety and tolerability of atogepant 10mg, 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine. [cited 2020 May 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT03777059
   Google Scholar
• Efficacy, safety, and tolerability of atogepant for the prevention of chronic migraine. [cited 2020 May 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT03855137
   Google Scholar
• Extension study to evaluate the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with episodic migraine. [ cited 3 May 2020]. Available from: https://clinicaltrials.gov/ct2/show/NCT03939312
   Google Scholar
• To evaluate the safety and tolerability of treatment with atogepant 60 mg daily for the prevention of migraine in participants with episodic migraine. [cited 2020 May 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT03700320
   Google Scholar
• Martin VT, Goldstein JA. Evaluating the safety and tolerability profile of acute treatments for migraine. Am J Med. 2005;118:36S–44S.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Reed ML, Kurth T, et al. Framingham-based cardiovascular risk estimates among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2017;57(10):1507–1521.
   PubMed Web of Science ®Google Scholar
• Barra S, Lanero S, Madrid A, et al. Sumatriptan therapy for headache and acute myocardial infarction. Expert Opin Pharmacother. 2010;11(16):2727–2737.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Golden W, Buse D, et al. Triptan use as a function of cardiovascular risk. A population-based study. Headache. 2010;50(2):256–263.
   PubMed Web of Science ®Google Scholar
• A study of lasmiditan on simulated driving performance in healthy participants (NCT03459612). [cited 2020 May 3]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT03459612
   Google Scholar
• Lionetto L, Capi M, Curto M, et al. Rimegepant. Drugs Future. 2019;44(8):635–642.
   Web of Science ®Google Scholar
• Tfelt-Hansen P, Loder E. The emperor’s new gepants: are the effects of the new oral CGRP antagonists clinically meaningful? Headache. 2019 Jan;59(1):113–117.
   PubMed Web of Science ®Google Scholar
• Martelletti P, Cipolla F, Capi M, et al. Atogepant. Drugs Future. 2020;45(5):285–297.
   Web of Science ®Google Scholar
• Cevoli S, D’Amico D, Martelletti P, et al. Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres. Cephalalgia. 2009 Dec;29(12):1285–1293.
   PubMed Web of Science ®Google Scholar